Pemigatinib is a first-generation targeted drug

Pemigatinib is a kinase inhibitor indicated for the treatment of patients with FGFR2 fusions or other rearrangements in patients with previously treated, unresectable locally advanced or Adults with metastatic cholangiocarcinoma (CCA) as detected by a U.S. Food and Drug Administration (FDA) approved test. Pemetinib is the first targeted therapy approved by the FDA for this indication and has received Breakthrough Therapy and Orphan Drug designations for this indication.

Pemetinibis a potent and selective small molecule kinase inhibitor that targetsFGFR1, FGFR2 and FGFR3. Constitutive FGFR signaling can lead to cancer cell proliferation. Pemetinibinhibits the phosphorylation and signaling of the FGFR1, 2, and 3 pathways, thereby reducing the proliferation of cancer cells through FGFR alterations. Pemetinib demonstrated antitumor activity in human tumor xenograft models with alterations in FGFR1, FGFR2, and FGFR3.

The original drug Pemetinib has been launched in China. Due to its short time on the market, it has not yet entered the scope of medical insurance. The price of each box of 9mg*14 tablets may be around 50,000 yuan, which is expensive. The original drug Pemetinib currently on the market overseas, with a specification of 13.5mg*14 tablets, may cost around RMB 70,000 per box (the price may fluctuate due to exchange rates). There are also generic pemetinib drugs produced in other countries overseas, and their drug ingredients are basically the same as those of the original drugs sold abroad. For example, the price of 4.5mg*14 tablets per box produced by a Laos pharmaceutical factory may be around 1,000 yuan (the price may fluctuate due to exchange rates).